Stay updated on Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page.

Latest updates to the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page
- Check2 days agoChange DetectedThe page revision indicator was updated from v3.5.3 to v3.5.4, indicating a newer build of the page. No user-facing content or study data were altered.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page shows Revision: v3.5.3, updating the prior revision tag from v3.5.2.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check45 days agoChange DetectedUpdated eligibility criteria now allow concurrent hormonal or anti-HER2 therapy if brain metastases progress; MRI criteria were revised to require at least 2 untreated measurable brain metastases (≥3 mm) within two weeks before treatment, and prior subtotal resection is permitted if residual disease <4 cm.SummaryDifference0.5%

- Check59 days agoChange DetectedSite revision history updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page.